STOCK TITAN
  1. Home
  2. Sec-filings
  3. KLRA
  4. [Form 4] Kailera Therapeutics, Inc. Insider Trading Activity

Kailera (KLRA) CEO exercises stock options, now holds 38,094 shares

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. CEO and President Ronald C. Renaud Jr. exercised stock options to acquire 38,094 shares of common stock at an exercise price of $5.25 per share on June 9, 2026. Following the transaction, he directly holds 38,094 common shares.

The exercised options covered 38,094 underlying shares out of a larger grant, with 817,826 stock options reported as remaining after the transaction and expiring on September 19, 2034. The options began vesting on September 9, 2025 and continue vesting in substantially equal monthly installments, conditioned on his continued service.

Positive

  • None.

Negative

  • None.
Insider Renaud Ronald C JR
Role CEO & President
Type Security Shares Price Value
Exercise Stock Option (right to buy) 38,094 $0.00 --
Exercise Common Stock 38,094 $5.25 $200K
Holdings After Transaction: Stock Option (right to buy) — 817,826 shares (Direct, null); Common Stock — 38,094 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares acquired via exercise 38,094 shares Common stock received by CEO on June 9, 2026
Option exercise price $5.25 per share Exercise price for 38,094 underlying shares
Shares held after transaction 38,094 shares Directly held Kailera common stock post-transaction
Options remaining 817,826 options Stock options reported outstanding after the exercise
Option expiration date September 19, 2034 Expiration of stock option grant exercised in part
Initial vesting date September 9, 2025 33% of options vested on this date
Vesting pattern 24 monthly installments Remaining options vest monthly, subject to continued service
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
exercise price financial
"conversion_or_exercise_price: "5.2500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2034-09-19T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Renaud Ronald C JR
(Last)(First)(Middle)
C/O KAILERA THERAPEUTICS, INC.
180 THIRD AVENUE, 4TH FLOOR
(Street)
WALTHAM MASSACHUSETTS 02451
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO & President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/09/2026M38,094A$5.2538,094D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$5.2506/09/2026M38,094 (1)09/19/2034Common Stock38,094$0817,826D
Explanation of Responses:
1. The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
/s/ John Mei, Attorney-in-fact06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Kailera Therapeutics (KLRA) disclose in this Form 4 filing?

Kailera Therapeutics reported that CEO Ronald C. Renaud Jr. exercised stock options to acquire 38,094 shares of common stock at $5.25 per share on June 9, 2026, increasing his directly held share position to 38,094 shares.

How many Kailera Therapeutics (KLRA) shares did the CEO acquire?

The CEO acquired 38,094 shares of Kailera Therapeutics common stock through a stock option exercise. These shares came from an existing option grant and represent his directly held common stock position after the reported transaction on June 9, 2026.

What was the exercise price of the Kailera Therapeutics (KLRA) options?

The options were exercised at an exercise price of $5.25 per share. This price applied to 38,094 underlying shares of Kailera Therapeutics common stock that CEO Ronald C. Renaud Jr. received through the reported stock option exercise.

Did the Kailera Therapeutics (KLRA) CEO sell any shares in this Form 4?

No share sales were reported in this Form 4. The filing only shows a stock option exercise, where the CEO converted options into 38,094 shares of common stock, with no corresponding sale transaction disclosed.

How many Kailera Therapeutics (KLRA) options remain after this exercise?

After exercising options for 38,094 shares, the filing shows 817,826 stock options remaining. These options relate to Kailera Therapeutics common stock and are reported with an expiration date of September 19, 2034.

What is the vesting schedule of the Kailera Therapeutics (KLRA) options exercised?

The options began vesting as to 33% of the total shares on September 9, 2025. The remaining portion vests in 24 substantially equal monthly installments, contingent on the CEO’s continued service through each vesting date.